Sorafenib for Prophylaxis of Leukemia Relapse in Allo-HSCT Recipients With FLT3-ITD Positive AML

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

202

Participants

Timeline

Start Date

June 20, 2015

Primary Completion Date

July 21, 2018

Study Completion Date

August 10, 2019

Conditions
Acute Myeloid LeukemiaHematopoietic Stem Cell Transplantation
Interventions
DRUG

Sorafenib

The initial dose of sorafenib is 400 mg orally twice daily and is adjusted in case of suspected toxicity or resistance (dose range, 200-800 mg daily).

Trial Locations (1)

510515

Department of Hematology,Nanfang Hospital, Southern Medical University, Guangzhou

All Listed Sponsors
collaborator

Peking University People's Hospital

OTHER

collaborator

Third Affiliated Hospital, Sun Yat-Sen University

OTHER

collaborator

Zhujiang Hospital

OTHER

collaborator

Xiangya Hospital of Central South University

OTHER

collaborator

First People's Hospital of Chenzhou

OTHER

collaborator

The First Affiliated Hospital of Guangzhou Medical University

OTHER

lead

Nanfang Hospital, Southern Medical University

OTHER

NCT02474290 - Sorafenib for Prophylaxis of Leukemia Relapse in Allo-HSCT Recipients With FLT3-ITD Positive AML | Biotech Hunter | Biotech Hunter